The placebo effect in neurological disorders. (Q35172494)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12849512%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

review article

1 reference

title

The placebo effect in neurological disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12849512%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

0 references

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12849512%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

Raúl de la Fuente-Fernández

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12849512%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Michael Schulzer

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12849512%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

publication date

1 June 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12849512%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12849512%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12849512%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12849512%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

85-91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12849512%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Cultural variations in the placebo effect: ulcers, anxiety, and blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Do medical devices have enhanced placebo effects?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Powerful placebo: the dark side of the randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Concept of true and perceived placebo effects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Placebo effect in double-blind clinical trials: a review of interactions with medications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

The mechanism of placebo analgesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

The double-blind, randomized, placebo-controlled trial: gold standard or golden calf?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

The importance of placebo effects in pain treatment and research

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

PSYCHOPHARMACOLOGY:Can the Placebo Be the Cure?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Double-blind trial of pergolide for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Objective changes in motor function during placebo treatment in PD

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Placebo and opioid analgesia-- imaging a shared neuronal network

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Neural mechanisms of antinociceptive effects of hypnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Changes in brain function of depressed subjects during treatment with placebo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Predictive reward signal of dopamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

The placebo effect in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Regional mu opioid receptor regulation of sensory and affective dimensions of pain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Clinimetric issues of screening for responsiveness to intrathecal baclofen in dystonia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Botulinum toxin A in non-dystonic tremors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Clonidine and Gilles de la Tourette's syndrome: double-blind study using objective rating methods

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Clonidine treatment of Gilles de la Tourette's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Intravenous benztropine and propranolol challenges in tardive akathisia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Placebo response in refractory tardive akathisia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Changes in tardive dyskinesia symptoms in elderly patients treated with ganglioside GM1 or placebo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Treatment of Obsessive-Compulsive Symptoms in Schizophrenic Patients With Clomipramine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Placebo-controlled trial of fluoxetine and phenelzine for obsessive- compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Brain dopamine and reward

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

The neural basis of drug craving: an incentive-sensitization theory of addiction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Reward deficiency syndrome: genetic aspects of behavioral disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Personality disorders and associated features in cocaine-dependent inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Comorbidity in a clinical sample of substance abusers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Attention-Deficit/Hyperactivity Disorder and Substance Use: Symptom Pattern and Drug Choice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Dopaminergic dysfunction in tourette syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Abnormal dopamine uptake sites in postmortem striatum from patients with tourette's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

123Ibeta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short-term behavioral effects in school settings

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Behaviorally conditioned immunosuppression and murine systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Dopamine, a neurotransmitter, influences the immune system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Bromocriptine in rheumatic and autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Dopamine in the striatum modulates seizures in a genetic model of absence epilepsy in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

Dopamine D4 receptor-deficient mice display cortical hyperexcitability

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900038-8

7 January 2021

10.1016/S1474-4422(02)00038-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12849512%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12849512%20AND%20SRC:MED&resulttype=core&format=json